Print Edition
TT On-The-Go
TT Feed
| Muslims prefer Iran to Europe for receiving medical treatment |
|
 |
 |
 |
Font Size 
|
Multithumb found errors on this page: There was a problem loading image C:\wamp\www\images/stories/08_prefer.jpg  TEHRAN – Professor Mostafa Yuksel, a renowned pioneer in thoracic surgery in Turkey, hailed Iran's progress in different medical fields, and said Muslims across the world prefer to receive medical treatment in Iran than Europe. "Muslims prefer Iran to Europe medically," Yuksel told FNA on the sidelines of his visit to Mashhad's Razavi hospital in Northeastern Iran on Saturday. He stressed that Muslims' interest and convenience in Iran has made the country popular among the world Muslims, and said, "I have seen many Turkish people who travel to Iran and Mashhad to receive heavy and difficult surgeries." In recent years, Iran has taken a wide stride in many areas of science and technology. Recently, Iranian Health Minister Marziyeh Vahid Dastjerdi announced that the country would soon start production of 15 types of anti-cancer drugs. "15 types of monoclonal anti-body drugs are being synthesized with the help of the Scientific Department of the Presidential Office, using hi-tech technology," Vahid Dastjerdi said. Noting that these anti-cancer drugs are now produced by only two to three western companies, she raised the possibility that the Iran-made monoclonal antibodies would be introduced to the Iranian market within the next two months. Monoclonal antibody drugs are a relatively new innovation in cancer treatment. While several monoclonal antibody drugs are available for treating certain cancers, the best way to use these new drugs isn't always clear. Also earlier this year, Iranian scientists succeeded in producing new types of medications for treating different kinds of cancer, viral diseases and arthritis with 100% positive results. "The medicine has been synthesized through a new and unique formula and has the capability to destroy all malignant cancerous cells," Head of the research team Qassem Tak Dehqan told reporters in April. In January, the Atomic Energy Organization of Iran (AEOI) announced that Iranian scientists have managed to synthesize two new types of radio-medicines to treat malignant types of cancer. "The Iranian scientists and researchers of the AEOI's Nuclear Science and Technology Research Center succeeded in producing two new radio-medicines for the first time to cure malignant cancers," AEOI Spokesman Hamid Khadem Qaemi said at the time. He named the radio-medicines as Lutetium-177 Phosphonate (EDTMP) for bone pain palliation in metastatic prostate cancer and Iodine 131 Chlorotoxin to treat malignant glioma. Also, Iran in December unveiled five different radio-medicine projects with applications for diagnosis, prevention and treatment of a number of diseases. In September 2010, Iran announced that it planned to synthesize 20 kinds of radio-medicine inside the country. "Iran has gained the necessary preparedness to produce 20 radio-medicines and we will provide the 20% (enriched nuclear) fuel needed for the production of these medicines this year," AEOI Deputy Head for Planning, International and Parliamentary Affairs Massoud Akhavan-Fard told FNA at the time. In addition to the Tehran research reactor which has long been used by radioisotope production, Iran also plans to build four other research reactors in the other parts of the country, he added. (Source: FNA)   Socialize this Subscribe to our RSS feed to stay in touch and receive all of TT updates right in your feed reader
|